France· FR:62624259
LITFULO 50 mg, gélule
A ritlecitinib product containing tosylate de ritlécitinib, registered in France by PFIZER EUROPE MA EEIG (BELGIQUE), on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Ritlecitinib is registered in 16 of 19 countries.
Countries holding a registration under ATC L04AF08 (ritlecitinib), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Ritlecitinib · ATC L04AF08
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- TOSYLATE DE RITLÉCITINIB
- Manufacturer
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Country
- France (FR)
- ATC code
- L04AF08
- ATC class
- Ritlecitinib
- Defined daily dose
- 50 mg, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930279724plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 30 gélule(s)EUR 971.74
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ritlecitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLitfuloU.S. Pharmaceuticals
- CzechiaLITFULOPfizer Europe MA EEIG, Bruxelles
- SwitzerlandLitfulo 50 mg, HartkapselnPfizer AG
- SpainLITFULO 50 MG CAPSULAS DURASPfizer Europe Ma Eeig
- FinlandLitfuloPfizer Europe MA EEIG
- United KingdomLitfulo 50mg capsulesPfizer Ltd
- BelgiumLitfulo 50 mgPfizer Europe MA
- IcelandLitfuloPfizer Europe MA EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Litfulo
- Liechtenstein · Litfulo
- Norway · Litfulo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/862beb83-23d1-478f-b2dd-b048366aad3e GET /v1/drugs/862beb83-23d1-478f-b2dd-b048366aad3e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62624259",
"date_amm": "2023-09-15",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1755",
"substance": "TOSYLATE DE RITLÉCITINIB",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about ritlecitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.